search
Back to results

Performance of Two Hydrophobic IOLs

Primary Purpose

Cataract

Status
Recruiting
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Enova GF3
Tecnis 1-piece ZCB00
Sponsored by
Vienna Institute for Research in Ocular Surgery
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cataract focused on measuring Cataract, Cataract surgery

Eligibility Criteria

21 Years - 105 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age-related bilateral cataract Age 21 or older Visual acuity > 0.05 Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Written informed consent prior to surgery Exclusion Criteria: Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), traumatic cataract, intraoperative Floppy Iris Syndrome (IFIS), or other co-morbidities that could affect capsular bag stability (e.g. Marfan syndrome) Any ophthalmic comorbidity that may compromise visual function or create problems with measurements (e.g. macular degeneration, amblyopia, corneal scars, etc.) Previous ocular surgery or trauma Pregnancy (pregnancy test will be taken in women of reproductive age)

Sites / Locations

  • Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital ViennaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Enova GF3

Tecnis 1-piece ZCB00

Arm Description

Patient will receive the monofocal IOL in one eye during cataract surgery

Patient will receive the monofocal IOL in one eye during cataract surgery

Outcomes

Primary Outcome Measures

Anterior chamber depth
Anterior chamber depth will be assessed using a biometry device and will be compared between both monofocal IOLs

Secondary Outcome Measures

IOL tilt
IOL tilt will be assessed using the purkinjemeter and will be compared between both IOLs
Posterior capsule opacification (PCO)
PCO will be assessed using retroillumination photography and will be compared between both groups
Visual acuity
Visual acuity will be assessed in the far and intermediate distance using ETDRS charts and will be compared between both groups
Catquest 9SF questionnaire
The Catquest 9SF questionnaire will be handed out to all patients

Full Information

First Posted
November 28, 2022
Last Updated
December 5, 2022
Sponsor
Vienna Institute for Research in Ocular Surgery
search

1. Study Identification

Unique Protocol Identification Number
NCT05639049
Brief Title
Performance of Two Hydrophobic IOLs
Official Title
Capsular Bag Performance of Two Hydrophobic Intraocular Lenses of Different Design
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
November 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Comparison of the capsular bag performance of two hydrophobic intraocular lenses of different design.
Detailed Description
Continuous improvements in cataract surgery technique, intraocular lens (IOL) materials, and design over the past few decades, have led to a more safe procedure with satisfactory refractive outcomes and a short rehabilitation time. By that, patients' expectations concerning their postoperative visual quality and refractive outcome are increasing. However, two main problems might occur after cataract surgery: instability of the IOL position in the capsular bag and formation of posterior capsule opacification (PCO). Both may decrease the optical performance of an IOL. The performance of an IOL depends on its behaviour in the capsular bag, which has an influence on the anterior chamber depth (ACD), as well as the postoperative refractive shift, the tilt and decentration of the IOL. Several factors such as IOL design and material, capsulorhexis size, capsular bag diameter, and capsular fibrosis or shrinkage may lead to a suboptimal IOL position. Misalignment of an IOL away from the retina leads to a myopic shift, while towards the retina leads to a hyperopic outcome. This explains why inaccurate prediction of postoperative ACD remains the main source of error in IOL power calculation. One main goal of modern cataract surgery is to yield a low and predictable ACD shift as well as low degrees of IOL tilt and decentration after surgery in order to achieve ideal optical performance of the IOL. Another aspect of capsular bag performance of an IOL is posterior capsule opacification (PCO). PCO is one of the most frequent long-term complications after cataract surgery leading to dissatisfying results by decreased visual function. Source of PCO are lens epithelial cells from the equator of the lens capsule, which acquire the ability to migrate and proliferate, causing epithelial ingrowth between the IOL and the posterior capsule. It is estimated that PCO occurs at a rate of 12% one year, 21% three years, and 28% five years after cataract surgery. PCO can be treated with neodymium-doped yttrium aluminium garnet (Nd:YAG) laser capsulotomy. However, complications including an increase in intraocular pressure, ocular inflammation, cystoid macular edema, and retinal detachment may occur after this treatment. Hence lower rates of PCO would improve patients long term safety following cataract surgery. Moreover, it would increase patient satisfaction. The material and design of an IOL may have an effect on the formation of PCO. Sharp optic edge design has been shown to be a major factor in the prevention of PCO. Furthermore, acrylic and silicone hydrophobic materials showed a lower risk for PCO formation and lower rates of postoperative Nd:YAG laser capsulotomy than hydrophilic IOLs. In this study the ACD shift and IOL tilt and centration as well as the PCO formation of an IOL with a new design, the Enova GF3 IOL will be compared to a standard monofocal IOL, the Tecnis 1-piece ZCB00. 90 eyes of 45 patients will be included into this study. According to the randomization, the ENOVA GF3 will be implanted in one eye and the ZCB00 in the fellow eye of each patient. Follow-up visits will take place 1 week, 3 months, 6 months, and 12 months after the surgery. At each visit a slitlamp examination, non-contact intraocular pressure measurement, refraction, visual acuity testing, biometry, retroillumination photography, and purkinjemeter assessments will be performed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
Cataract, Cataract surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Enova GF3
Arm Type
Experimental
Arm Description
Patient will receive the monofocal IOL in one eye during cataract surgery
Arm Title
Tecnis 1-piece ZCB00
Arm Type
Experimental
Arm Description
Patient will receive the monofocal IOL in one eye during cataract surgery
Intervention Type
Device
Intervention Name(s)
Enova GF3
Intervention Description
Enova GF3, monofocal IOL
Intervention Type
Device
Intervention Name(s)
Tecnis 1-piece ZCB00
Intervention Description
Tecnis 1-piece ZCB00, monofocal IOL
Primary Outcome Measure Information:
Title
Anterior chamber depth
Description
Anterior chamber depth will be assessed using a biometry device and will be compared between both monofocal IOLs
Time Frame
24 months
Secondary Outcome Measure Information:
Title
IOL tilt
Description
IOL tilt will be assessed using the purkinjemeter and will be compared between both IOLs
Time Frame
24 months
Title
Posterior capsule opacification (PCO)
Description
PCO will be assessed using retroillumination photography and will be compared between both groups
Time Frame
24 months
Title
Visual acuity
Description
Visual acuity will be assessed in the far and intermediate distance using ETDRS charts and will be compared between both groups
Time Frame
24 months
Title
Catquest 9SF questionnaire
Description
The Catquest 9SF questionnaire will be handed out to all patients
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age-related bilateral cataract Age 21 or older Visual acuity > 0.05 Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Written informed consent prior to surgery Exclusion Criteria: Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), traumatic cataract, intraoperative Floppy Iris Syndrome (IFIS), or other co-morbidities that could affect capsular bag stability (e.g. Marfan syndrome) Any ophthalmic comorbidity that may compromise visual function or create problems with measurements (e.g. macular degeneration, amblyopia, corneal scars, etc.) Previous ocular surgery or trauma Pregnancy (pregnancy test will be taken in women of reproductive age)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christoph Spartalis, MD
Phone
01 91021
Ext
57564
Email
office@viros.at
First Name & Middle Initial & Last Name or Official Title & Degree
Manuel Ruiss, MSc
Phone
01 91021
Ext
57564
Email
office@viros.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, Prof. Dr.
Organizational Affiliation
Vienna Institute for Research in Ocular Surgery
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, MD, MBA
Phone
+43 91021
Ext
57564
Email
office@viros.at

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Performance of Two Hydrophobic IOLs

We'll reach out to this number within 24 hrs